We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Bioequivalence of Levothyroxine Preparations for Treatment of Hypothyroidism-Reply

Betty J. Dong, PharmD; John G. Gambertoglio, PharmD; Francis S. Greenspan, MD; Walter W. Hauck, PhD
JAMA. 1997;277(15):1199-1200. doi:10.1001/jama.1997.03540390029020.
Text Size: A A A
Published online


In Reply.  —The letter from Dr Spigelman contains several inaccuracies and misconceptions.Treatment guidelines from the leading thyroid societies all were prepared before publication of current data so that current guidelines may need to be updated.1,2 It should be noted that these treatment guidelines do not actually recommend that retitration is necessary once levothyroxine brands are changed. Previous reports of levothyroxine nonequivalence studied products that were formulated before the adoption of the US Pharmacopeia (USP) guidelines. These guidelines require all manufacturers to monitor and assure the tablet levothyroxine content, thus reducing the potential for tablet subpotency to affect thyroxine equivalence. The high-performance liquid chromatography analysis of the tablet levothyroxine content of our study preparations, despite some variability in our assay, met FDA specifications for proper levothyroxine content. Slight differences in tablet content did not significantly change our results or the analysis by Mayor et al.3 Clinical interchangeability in patients given


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.